Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RGRX one for 100 reverse split:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
scam bullshit is shell risk now
scam bullshit is shell risk now
RGRX...16...Bullish Harami Cross Reversal Pattern formed to the Upside as the Bollies start to Squeeze...
RGRX...Looking for RGRX to Break the .16/.20 Consolidation Channel to the Upside and make a run at the previous high of .82 should they have positive news from the FDA meeting...imo...we shall see...
Chart... https://schrts.co/cbFeWPua ...
Will be adding more for the February FDA meeting...
ROCKVILLE, Md., Dec. 17, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. FDA has accepted its request for a pre-BLA meeting pursuant to RGN-259, its novel product candidate for dry eye syndrome. The meeting is scheduled for February 28, 2022. A BLA (Biologics License Application) is FDA's standard "full approval" mechanism for biological products, including therapeutics and vaccines.
dont they all bust balls until they dont
It's fine...they are reinforced...
she likes to bust your balls alright
RGRX...1875...Trying to Break the .20 Resistance point...
georgie18 Member Level Tuesday, 11/30/21 08:14:51 AM
Re: georgie18 post# 345 0
Post #
346
of 346
RGRX...16...Breaking the Descending Triangle here as RGRX pushing for the Upper Channel Break...imo...we shall see...
Chart... https://schrts.co/aRfQYXvU ...
RGRX...16...Breaking the Descending Triangle here as RGRX pushing for the Upper Channel Break...imo...we shall see...
Chart... https://schrts.co/aRfQYXvU ...
Yes indeed...been accumulating for that day....certainly tries one's patience...
RGRX...1675...Bullish Harami Cross Reversal Pattern to the Upside on this Oversold Williams...adding on this Pattern...
Chart...https://schrts.co/XgYaVXyM ...
Authorized Shares
200,000,000
10/18/2021
Outstanding Shares
143,549,735
10/18/2021
Held at DTC
71,886,334
10/18/2021
Float
69,090,013
08/31/2021
Shareholder letter today tells of ARISE-3 rising from the ashes!!!
RGRX...30s starting here...strong Marubozu Candle...needs some strong volume as a follow through...imo...we shall see...:party:
[10:11 AM]
georgie18 — 03/21/2021
RGRX...2575...Bullish Meeting Line Reversal Pattern to the Upside on this Oversold Pincher Chart...
Loaded under .30 to triple my holdings...and average down...after some negative test results...
Looking for the Gap to fill in the .60 range given time...:party:
Why? This company is going to have to initiate a whole new trial which will take years and they will most likely dilute to do it as is the usual process with biotechs that fail their phase 3. Why would this get back to .60 barring a new successful phase 3 that will take years?
RGRX...2575...Bullish Meeting Line Reversal Pattern to the Upside on this Oversold Pincher Chart...
Loaded under .30 to triple my holdings...and average down...after some negative test results...
Looking for the Gap to fill in the .60 range given time...
Chart...https://schrts.co/KIhGjKuU ...
it takes 6 months to hear from FDa
I agree! And sorry, but not a clue!
Big news! Any ideas how long the statistical analysis should take?
GTRIBNT completes phase 3 clinical trial for dry eye syndrome (ARISE-3) data lock-up
By GtreeBNT 2021 years 2 24-days Mon. - , Press Releases
GTRIBNT (115450) is a data lock-up that prevents modification of all numbers and information of clinical data conducted at 20 hospitals across the United States for ARISE-3, phase 3 clinical trial of dry eye treatment (RNG-259). It was announced on the 24th that it was completed.
A GTRIBNT official said, "We have completed data cleaning, which is the current ARISE-3 clinical data cleanup task, and have completed Data Lock-Up to confirm and collect clinical data in 20 US hospitals." As soon as the statistical analysis of variables as well as all endpoints in the protocol is completed, the results will be disclosed in Korea and the United States, especially as some multinational companies are already waiting for the results of ARISE-3 I will derive data.”
GTRIBNT has already secured major intellectual property rights such as patents for compositions and pharmaceutical formulations, and patents for manufacturing method of eye drops for future market monopoly along with the progress of phase 3 clinical trials related to the development of new dry eye drugs, as well as the US FDA. As the product approval process is divided into a biologics license application (BLA), a 12-year monopoly on the new drug market can be granted upon approval.
Meanwhile, in a report published in June 2020 regarding the dry eye treatment market,'Global Data', an overseas analysis agency, predicts the dry eye treatment market in 9 countries, including the United States, at 13 trillion won. Compared to Zydra, Gtree B&T's RGN-259 is predicted to have the largest cumulative sales from 2022 to 2028, as it has a competitive edge in that it has no discomfort such as a burning sensation and rapid drug expression.
https://lveulxwbijija56pkhqkk4tgee-adwhj77lcyoafdy-gtreebnt-com.translate.goog/2021/02/24/%ec%a7%80%ed%8a%b8%eb%a6%ac%eb%b9%84%ec%95%a4%ed%8b%b0-%ec%95%88%ea%b5%ac%ea%b1%b4%ec%a1%b0%ec%a6%9d-%ec%b9%98%eb%a3%8c%ec%a0%9c-%ec%9e%84%ec%83%81-3%ec%83%81arise-3-data-lock-up-%ec%99%84%eb%a3%8c/
Would be nice 0001 but the problem is China ???? too cheap..
Also they have already used our drug for other indications..
But Tb4 going global treating Dry eye and other things like Covid19.. Sure 45 dolla luv me long time..
GL longs